BAA availability is table stakes; HITRUST is the real differentiator
Nearly every serious AI scribe will now sign a BAA — the question has shifted to whether that BAA is available at the small-clinic entry price or gated behind a mid-market tier. HITRUST, by contrast, remains rare and expensive, which is why it disproportionately correlates with hospital-system procurement approval.